Skip to main content
Loading

Development of multiplex technologies to develop combination drug strategies

24 Sep 2024
Sonoma
Tumor Microenvironment (TME)
  • Induction of checkpoints and other components of tumor immunity
  • Breaching the TME
  • Tumor cell killing and other surrogates for overall survival
Industry Expert
Pamela Reilly Contag, PhD, Chief Executive Officer - BioEclipse Therapeutics